Evidence map›Paper›PMID 22322600›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2012

Tannic acid down-regulates the angiotensin type 1 receptor through a MAPK-dependent mechanism.

Rekha Yesudas, Upendra Gumaste, Russell Snyder, Thomas Thekkumkara

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rekha YesudasDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center, 1300 Coulter Drive, Amarillo, TX 79106, USA.
Upendra Gumaste
Russell Snyder
Thomas Thekkumkara
Texas Tech University Health Sciences Center · USTexas Tech University · US

Funding

ROLE OF GLUCOSE IN hAT1 GENE EXPRESSIONR01DK072140 · NIDDK · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI THEKKUMKARA, THOMAS J · 2006 to 2009
$1.2M
NIDDK NIH HHS DK072140NIDDK NIH HHS R01 DK072140
6 · The paper itself

Abstract

In the present study, we investigated the effects of tannic acid (TA), a hydrolysable polyphenol, on angiotensin type 1 receptor (AT1R) expression in continuously passaged rat liver epithelial cells. Under normal conditions, exposure of cells to TA resulted in the down-regulation of AT1R-specific binding in concentrations ranging from 12.5-100 μg/ml (7.34-58.78 μm) over a time period of 2-24 h with no change in receptor affinity to angiotensin II (AngII). The inhibitory effect of TA on AT1R was specific and reversible. In TA-treated cells, we observed a significant reduction in AngII-mediated intracellular calcium signaling, a finding consistent with receptor down-regulation. Under similar conditions, TA down-regulated AT1R mRNA expression without changing the rate of mRNA degradation, suggesting that TA's effect is mediated through transcriptional inhibition. Cells expressing recombinant AT1R without the native promoter show no change in receptor expression, whereas a pCAT reporter construct possessing the rat AT1R promoter was significantly reduced in activity. Furthermore, TA induced the phosphorylation of MAPK p42/p44. Pretreatment of the cells with a MAPK kinase (MEK)-specific inhibitor PD98059 prevented TA-induced MAPK phosphorylation and down-regulation of the AT1R. Moreover, there was no reduction in AngII-mediated intracellular calcium release upon MEK inhibition, suggesting that TA's observed inhibitory effect is mediated through MEK/MAPK signaling. Our findings demonstrate, for the first time, that TA inhibits AT1R gene expression and cellular response, suggesting the observed protective effects of dietary polyphenols on cardiovascular conditions may be, in part, through inhibition of AT1R expression.

Indexed as

MAP Kinase Signaling SystemAngiotensin II Type 1 Receptor BlockersAnimalsBinding, CompetitiveCalcium SignalingCells, CulturedDown-RegulationEnzyme ActivationEpithelial CellsLosartanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PhosphorylationPromoter Regions, GeneticRatsReceptor, Angiotensin, Type 1Angiotensin II Type 1 Receptor BlockersLosartanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Receptor, Angiotensin, Type 1RNA, MessengerTannins

Identifiers

PMID22322600
PMCPMC3286191
OpenAlexW2121299772

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.